Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence: a Prospective, Multicenter, Randomized Phase II Study

NCT06812039 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06812039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06812039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence: a Prospective, Multicenter, Randomized Phase II Study
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
January 1, 2025
Completion date
January 31, 2028
Enrollment
165 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepato cellular carcinoma (hcc)